Bagsværd, Denmark, 21 November 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy ® 100/3.6. Xultophy ® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).
Xultophy ® 100/3.6, the approved brand name for IDegLira in the US, is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba ® ) and the GLP-1 analogue liraglutide (Victoza ® ). In the DUAL phase 3 clinical trial programme, Xultophy ® 100/3.6 consistently showed an improvement of glycaemic control in adults with type 2 diabetes uncontrolled on liraglutide or basal insulin therapy. For adults inadequately controlled on insulin glargine U100, treatment with Xultophy ® 100/3.6 demonstrated a reduction in HbA 1c of 1.7% after 26 weeks. Xultophy ® 100/3.6 can be taken at the same time each day with or without food and will be available in a prefilled pen.
"We are pleased with the approval of Xultophy ® 100/3.6 and look forward to launching it in the US in the first half of 2017", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We believe Xultophy ® 100/3.6 offers significant benefits and is an important and convenient treatment option especially for people not achieving sufficient glycaemic control with basal insulin".
The approval follows the recommendation of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), which voted 16-0 in favour of an approval of Xultophy ® 100/3.6 for the treatment of adults with type 2 diabetes, at its meeting on 24 May 2016.
Xultophy ® 100/3.6 is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba ® ) and the GLP-1 analogue liraglutide (Victoza ® ). The Xultophy ® 100/3.6 pen delivers doses from 10 to 50 units with each injection. Each unit of Xultophy ® 100/3.6 contains 1 unit of insulin degludec and 0.036 mg of liraglutide.
|Katrine Sperling||+45 3079 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 786 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Melanie Raouzeos||+45 3075 email@example.com|
|Hanna Ögren||+45 3079 firstname.lastname@example.org|
|Anders Mikkelsen||+45 3079 email@example.com|
|Kasper Veje (US)||+1 609 235 firstname.lastname@example.org|
Company announcement No 82 / 2016PR161121_Xultophy_FDA_UK
Last updated on: 23/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.